Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Rituximab 66 Cyclophosphamide 52 fludarabine phosphate 26 fludarabine 22 Filgrastim 21 Vincristine 19 Methotrexate 19 Melphalan 19 Doxorubicin 18 Radiotherapy 17 Etoposide 17 Prednisone 16 Tacrolimus 15 Whole-Body Irradiation 14 Mycophenolic Acid 14 Cytarabine 14 Peripheral Blood Stem Cell Transplantation 13 Gemcitabine 13 Cyclosporine 13 Antilymphocyte Serum 13 Lenalidomide 12 Busulfan 11 Bortezomib 11 Granulocyte Colony-Stimulating Factor 9 Alemtuzumab 9 sargramostim 8 Dexamethasone 8 Cord Blood Stem Cell Transplantation 8 pembrolizumab 7 ibritumomab tiuxetan 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Lymphoma × Tolbutamide × Clear all

NCT01185548 2018-10-19

JZAR

Eli Lilly and Company

Phase 1 Terminated

4 enrolled 8 charts

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡